Current Landscape of Antibody-Drug Conjugate Development in Head and Neck Cancer
Jong Chul Park1,2, Donghoon Shin3
1Massachusetts General Hospital, Boston, MA.
Abstract:
Antibody-drug conjugates (ADCs) are fusions of therapeutic drugs and antibodies conjugated by a linker, designed to deliver a therapeutic payload to cells expressing the target antigen. By delivering the highly cytotoxic agent directly to cancer cells, ADCs are designed to enhance safety and broaden the therapeutic window. Recently, ADCs have demonstrated promising efficacy in various solid tumors and are rapidly expanding their indications. The prognosis of patients with advanced head and neck squamous cell carcinoma (HNSCC) remains poor, with no new therapeutics since the advent of anti-PD-1 antibodies in 2016, highlighting a critical need for innovative therapies. Recent preliminary results suggest that ADCs could be promising treatment options for HNSCC as they explore a variety of target antigens, payloads, and linkers. However, for successful adaptation of ADCs in the treatment of HNSCC, addressing key challenges such as payload toxicities, antigen heterogeneity, and adaptive resistance will be essential. Current research focused on new ADC structures, including multispecific antibodies and noncytotoxic payloads, and diverse combination approaches, show promise for future advancements.
Insights
Antibody-drug conjugates (ADCs) show promise for treating head and neck squamous cell carcinoma (HNSCC). Overcoming challenges like toxicity and resistance is key for their successful adaptation in HNSCC therapy.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Advanced head and neck squamous cell carcinoma (HNSCC) has a poor prognosis with limited therapeutic advancements since 2016.
- Antibody-drug conjugates (ADCs) offer targeted delivery of cytotoxic agents, enhancing safety and therapeutic windows for cancer treatment.
- ADCs are increasingly demonstrating efficacy in solid tumors, prompting exploration for HNSCC treatment.
Purpose of the Study:
- To evaluate the potential of antibody-drug conjugates (ADCs) as a novel therapeutic strategy for advanced head and neck squamous cell carcinoma (HNSCC).
- To highlight the critical need for innovative therapies in HNSCC due to the stagnation of treatment options.
- To review preliminary findings and ongoing research regarding ADCs in HNSCC.
Main Methods:
- Exploration of various target antigens, payloads, and linker technologies for ADC development in HNSCC.
- Analysis of preliminary results from ADC investigations in HNSCC models or patient populations.
- Review of current research focusing on novel ADC structures and combination strategies.
Main Results:
- Preliminary results indicate that ADCs targeting specific antigens may be effective against HNSCC.
- ADCs offer a potential new therapeutic avenue for HNSCC, distinct from current immunotherapies.
- Research is actively exploring diverse ADC designs and combinations for improved HNSCC treatment.
Conclusions:
- ADCs represent a promising therapeutic option for advanced HNSCC, addressing a significant unmet medical need.
- Key challenges including payload toxicity, antigen heterogeneity, and adaptive resistance must be addressed for successful clinical translation.
- Ongoing research into novel ADC architectures and combination therapies holds potential for future advancements in HNSCC treatment.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:31Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...